University of Nottingham Technology transfer team praised for £12m impact

The University of Nottingham’s Technology Transfer Office (TTO) has been nationally recognised by the Biotechnology and Biological Sciences Research Council (BBSRC) for its work in commercialising technologies arising from research into Clostridia.

The team from The University of Nottingham was one of just six from universities across the UK, to be shortlisted to pitch to the BBSRC for the Activating Impact award.

Secured over £12m of funding

As a result of the work of the TTO at Nottingham, the University has, since 2006, obtained over £12 million of commercial and government funding for the development of new technologies and research into this area.

Bacteria have been genetically modified for several decades, but many of the most useful ‘industrial biotechnology’ bacteria are recalcitrant to such manipulation. However, the Clostridia Research Group led by Professor Nigel Minton, has developed a number of revolutionary techniques which allowed the efficient modification of the organism’s genome.

The first technology was ClosTron which was an innovative adaptation of an existing technology that enabled its deployment in clostridia. Since then, his group has developed several new proprietary methods which have led to four patent families. These patents are being exploited to lever in research funding and as the basis of licence deals with industrial biotechnology companies.

Genetically manipulated to produce biofuel
The University’s TTO filed patent applications for further developments of the clostridia based technologies. One of these was a technology known as ACE (Allele-Coupled Exchange).
ACE is a methodology which allows the scientist to produce a microbe that has been genetically manipulated to produce the biofuel butanol and potential grow on biomass. This technology was one of the major elements in the University’s bioenergy proposals which led to a £10m investment from the BBSRC in a Bioenergy Centre at the University.

Exciting techniques and technologies
Dr Celia Caulcott, Director of Innovation and Skills, BBSRC said: “Our Fostering Innovation competitions develop partnerships, increase participation, promote innovation and help researchers deliver important knowledge and benefits for people around the world.

“This is the age of bioscience with exciting techniques and technologies from the UK’s world class research offering enormous potential and possibilities in tackling some of the great challenges we face.

“I would like to congratulate The University of Nottingham’s technology transfer office for the great work they have done in exploiting the commercial potential of technologies arising from their research into clostridia.”

In addition to the multi-millions of pounds of funding that the Technology Transfer Office has secured from commercial and government sources,  four patents have been filed for the genetic manipulation of clostridia, 24 commercial licences have been granted and over 250 material transfer agreements have been drafted.

Support for academics and businesses wanting to license ideas
Dr. Susan Huxtable, Director of Intellectual Property and Commercialisation at the University, commented: “The excellent work that the technology transfer team has done with Professor Minton and his technologies is a great example of the support that we offer to academic staff at the University, as well as to businesses wanting to license innovative new ideas.

“The team has managed his patent portfolio along with his research and studentship contracts and the many requests for his materials. This has ensured that the income from IP has been maximised to get the very best value for the University and from BBSRC’s investment in Professor Minton’s work.”
Global interest in the technologies
Professor Minton’s technologies have received huge interest from academic groups worldwide, as well as interest from numerous companies in a diverse range of sectors. The University’s TTO also manages all requests from academic or commercial groups that want to access Professor Minton’s patents and receive materials (plasmids).
Professor Minton added: “I am extremely grateful for the invaluable professional service that the TTO has provided to me, my team and the technologies for genetically modifying Clostridium that we have developed over the years.
“Due to this, we are now in a very strong position to commercially exploit future applications from the technologies in areas such as sustainable biofuel production, fine chemicals and novel therapeutics in fields such as cancer and microbial-induced diseases.”

For more information about the technology transfer services that the University provides to businesses, visit

Subscribe to get the latest news